First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $2.97B |
| Expense Ratio | 0.55% |
| PE Ratio | 27.39 |
| Shares Out | 10.90M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 32,818 |
| Open | 272.37 |
| Previous Close | 273.91 |
| Day's Range | 266.95 - 272.37 |
| 52-Week Low | 171.23 |
| 52-Week High | 274.81 |
| Beta | 0.66 |
| Holdings | 32 |
| Inception Date | Jun 19, 2006 |
About FBT
Fund Home PageThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.
Top 10 Holdings
38.22% of assets| Name | Symbol | Weight |
|---|---|---|
| Halozyme Therapeutics, Inc. | HALO | 4.28% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.93% |
| Corcept Therapeutics Incorporated | CORT | 3.90% |
| BeOne Medicines AG | ONC | 3.86% |
| NeoGenomics, Inc. | NEO | 3.77% |
| Repligen Corporation | RGEN | 3.76% |
| BioMarin Pharmaceutical Inc. | BMRN | 3.76% |
| Natera, Inc. | NTRA | 3.73% |
| Amgen Inc. | AMGN | 3.73% |
| Genmab A/S | GMAB | 3.50% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 13, 2024 | $1.1726 | Dec 31, 2024 |
| Sep 23, 2015 | $0.0197 | Sep 30, 2015 |
| Jun 24, 2015 | $0.0649 | Jun 30, 2015 |
| Mar 25, 2015 | $0.0476 | Mar 31, 2015 |
| Dec 23, 2014 | $0.0524 | Dec 31, 2014 |
| Jun 23, 2008 | $0.2697 | Jun 30, 2008 |
Performance
FBT had a total return of 55.14% in the past year, including dividends. Since the fund's inception, the average annual return has been 13.81%.
News
Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar
Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
Biotech ETFs at two-week highs on upbeat vaccine news
Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.